Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease
Clinical trial NCT00842088 · COMPLETED
Trial details
- NCT number
- NCT00842088
- Sponsor
- HemaQuest Pharmaceuticals Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2009-03-01
- Primary completion
- 2010-07-01
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.